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Background: General practitioners (GPs) often fail to correctly adhere to guidelines for the treatment of
hypertension. The reasons for this are unclear, but could be related to lack of knowledge in assessing individual
patients' cardiovascular disease risk. Our aim was to investigate how GPs in southern Sweden adhere to clinical
guidelines for the treatment of hypertension when major cardiovascular risk factors are taken into
consideration.
Method: A questionnaire with five genuine cases of hypertension with different cardiovascular risk profiles was
sent to a random sample of GPs in southern Sweden (n = 109) in order to investigate the attitude towards
blood pressure (BP) treatment when major cardiovascular risk factors were present.
Results: In general, GPs who responded tended to focus on the absolute target BP rather than assessing the
entire cardiovascular risk factor profile. Thus, cases with the highest risk of cardiovascular disease were not
treated accordingly. However, there was also a tendency to overtreat the lowest risk individuals. Furthermore,
the BP levels for initiating pharmacological treatment varied widely (systolic BP 140-210 mmHg). ACE inhibitors
(70%) were the most common first choice of pharmacological treatment.
Conclusion: In this study, GPs in Southern Sweden were suggesting, for different cases, either under- or
overtreatment in relation to current guidelines for treatment of hypertension. On reason may be that they
failed to correctly assess individual cardiovascular risk factor profiles.
Key points: Despite international and national clinical guidelines on the treatment of hypertension, general
practitioners often fail to correctly assess the cardiovascular risk for patients in a clinical setting.
● Most GPs use target blood pressure levels but do not consider other cardiovascular risk factors.
● Both under- and overtreatment of high and low cardiovascular risk groups were seen in this study.
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High blood pressure (BP) is an important risk factor
for cardiovascular disease [1]. In accordance with offi-
cial guidelines [2], the overall cardiovascular risk
should be taken into account before pharmacological
treatment of high BP begins. There are a number of
risk factors for developing manifest cardiovascular* Correspondence: rickard.ekesbo@skane.se
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reproduction in any medium, provided the ordisease, most important of which are age, family his-
tory, gender, smoking, diabetes, hypercholesterolemia,
low physical activity and low consumption of fruit and
vegetables [3].
In spite of clear guidelines on the treatment of high
BP and the availability of a number of tools for risk
assessment, there is large variation in the way that dif-
ferent GPs initiate treatment for high BP. Furthermore, a
large proportion of patients with high BP receive no or
inadequate treatment [4].
In a previous study from our group, only 20% of patients
treated from hypertension in primary care in southernLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(<140/90 mmHg) [5]. This result illustrated the need for
continued follow-up of defined groups of patients in order
to improve the quality of care.
Furthermore, three main barriers towards implement-
ing guidelines were identified among GPs: doubt con-
cerning patient motivation, patient age and absence of
other risk factors [6].
These previous findings reflect the problem that while
guidelines are clear and concise, real patients are, in their
nature, much more complex. The aim of this study was
to investigate how GPs in southern Sweden adhere to
clinical guidelines for the treatment of hypertension,
using a case-based questionnaire to reflect patients' com-




Skåne County is situated in the southernmost part of
Sweden and has approximately 1,150,000 inhabitants.
Primary care is provided by approximately 600 GPs, of
whom 420 are employed by public primary health care
centres. Of these 90 primary care centres, 24 centres
(employing a total of 109 GPs) were randomly selected
for participation in the survey and is thus believed to be
a cross-section of the GP´s of the area. An invitation letter,
including self-administered questionnaires (see below) was
sent to the head of each primary health care centre during
2006. Non-responders received telephone reminders. For
each primary health care centre agreeing to participate in
the survey, all physicians working at the centre were asked
to fill out questionnaires on attitudes towards current
guidelines [1,2] and general practice in the treatment of
high BP.
No data were collected for the 19 GPs who did not fill
in the questionnaires.
Questionnaires
The survey included two postal questionnaires. Sex and
information on professional experience was recorded
for all GPs. The results of the first questionnaire have
previously been published [6]. The second questionnaire
included four questions based on five genuine cases of
high BP with different cardiovascular risk profiles (see
below). The five cases were based on true cases and
intended to represent reasonable variation of hypertensive
patients with different risk profiles common in primary
care practice. Thus, the cases represent various levels
of risk rather than being absolutely representative for
the hypertensive population of the region. Such a co-
hort could possibly present a different pattern but
might also give a less clear picture for decision-making
regarding hypertension.The following four specific questions were used for each
case:
1. Do you find that drug treatment is indicated for this
patient?
2. If so, what is your first choice of drug class for
treatment?
3. What is your target BP?
4. What other cardiovascular disease (CVD) risk
factors do your think should be considered when
choosing an intervention?
Possible answers to the first question were “yes” or “no”.
The second question included six alternative answers:
“beta blockers”, “diuretics”, “ACE inhibitors”, “angiotensin
receptor blockers (ARBs)”, “calcium channel blockers” and
“other”. Questions 3 and 4 were open, without predefined
answers to choose from; however reported CVD risk fac-
tors (question 4) were later categorized into four groups:
hyperglycemia or diabetes, smoking, hyperlipidemia and
obesity.
Data for each case were registered separately. The cases
were assessed using two different risk assessment instru-
ments: the SCORE, which is intended to assess cardiovas-
cular disease mortality risk in patients without manifest
cardiovascular disease and which is based on subject
gender, age, systolic blood pressure, smoking status and
cholesterol levels [2]; and the joint European Society of
Hypertension (ESH) and European Society of Cardiology
(ESC) risk assessment instruments, which take into ac-
count other risk factors and which also cover patients
with manifest cardiovascular complications [1].Statistical methods
Only descriptive data were used in this study.Results
The results are presented as individual cases, followed by
interpretation of the results and adherence to guidelines
according to the SCORE and ESC scoring systems. A
short version is shown in Table 1.Case 1 facts: female, age 45 years, BP 160/95
Family history of cardiovascular disease. Non-smoker.
Married with two children. Administrative work with low
stress. Exercises three days a week. Previously had high
blood pressure about 10 years ago, as measured by her
occupational health physician and received drug treat-
ment for a short period. BMI: 25 kg/m2. ECG: normal.
Routine tests (full blood count and routine biochemistry):
no abnormalities detected (NAD). Serum cholesterol:
5.6 mmol/l.
Table 1 The cases in short form with risk factors and response rate for treatment




Heredity Score ESC Proportion
treating (%)
1 160/90 0 5.6 0 0 0-1 1 92
2 160/95 0 6.7 LVH 0 2 2 99
3 150/80 + 5.0 0 0 NA 2 94
4 150/80 0 4.0 CABG + NA 3 70
5 155/85 0 6.2 ? ? NA 2 58
LVH= Left ventricular hypertrophy. CABG=Coronary artery bypass graft.
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Case 1 represents a case of low CVD risk, being a non-
smoking female with mild hypertension. According to
the risk assessment, case no 1 has a SCORE of 0-1 and
an ESC score of 1. Thus, the risk for manifest CVD dis-
ease within 10 years is very low (1-2%) and blood pres-
sure treatment may not be indicated.
Case 1 results
In this case, 92% of the GPs found a drug treatment indi-
cation for hypertension. The target systolic blood pres-
sure was 140 for 83% of responders and the diastolic
blood pressure 90 in 46% of responders.
Among those who found a drug treatment indication,
73% selected diuretics as their first choice of treatment
and 25% ACE inhibitors or ARBs. 28 and 29% of GPs, re-
spectively, thought that the cholesterol levels and the
weight also should be treated.
Case 2 facts: female, age 54 years, BP 160/95
No family history of cardiovascular disease. Non-smoker.
Married with two children. Originally from Greece. Man-
ual worker. Slight obesity. No daily exercise. Blood pres-
sure repeatedly measured to be 160/95. Patient reports
occasional palpitations and decreasing physical condition.
Physical examination reveals a murmur in the left carotid
artery. BMI: 30 kg/m2. ECG: suspected left ventricular
hypertrophy (LVH). Routine tests: NAD. Serum-cholesterol:
6.7 mmol/l.
Case 2 risk assessment
This patient represents a medium cardiovascular risk,
having suspected left ventricular hypertrophy. She has a
SCORE of 2 and an ESC score of 2. With hypertension
in the medium range, this patient should be treated. Tar-
get organ damage (TOD) should be addressed.
Case 2 results
Almost all GPs (99%) chose to treat the blood pressure.
Of these, 43% selected ACE-I as their first choice of
treatment, followed by diuretics (23%) and beta blockers
(10%). 41% of the GPs thought that the raised serum
cholesterol should be treated.Case 3 facts: male, age 56 years, BP 150/80
Family history of diabetes, but not heart disease. Non-
smoker. Married with two children. Taxi driver. Low exer-
cise levels. Diabetes since the age of 5; treated with diet and
oral antidiabetics; no organ complications. Blood pressure
measured to be 150/80 (by his GP) and 145/80 (by his dia-
betes nurse). BMI: 28 kg/m2. ECG: normal. Routine tests:
NAD. Serum creatinine: 74 mmol/l. Microalbuminuria:
negative. Serum cholesterol: 5,0 mmol/l. HgbA1c: 6.8%.Case 3 risk assessment
This case represents a medium cardiovascular risk with
diabetes and an unsatisfactory blood pressure. Due to
the presence of diabetes mellitus type 2 SCORE cannot
be assessed. The ESC score is 2.Case 3 results
94% of the GPs wanted to treat the hypertension, the
majority of whom (79%) selected ACE inhibitors as the
first choice of treatment. The target BP levels for most
was 130/80, which is the recommended value for diabetic
patients [1]. 26 and 22% of the GPs, respectively, wanted
to increase the treatment of hyperglycemia and hyperlipid-
emia, whereas 41% wished to treat the patient's overweight.Case 4 facts: female, age 62 years, BP 150/80
Family history of coronary heart disease on the maternal
and paternal sides. Married. Newspaper delivery person.
Coronary artery bypass graft (CABG) five years ago due to
angina problems. Current medication: metoprolol 50 mg×1,
pravastatin 40 mg × 1, felodipin 10 mg × 1 and aspirin
75 mg×1. Smokes 20 cigarettes per day. No current angina.
Home-measured BP around 140/80; nurse-measured blood
pressure 150/80; GP-measured BP 145/80. BMI: 25 kg/m2.
ECG: normal. Routine tests: NAD. Serum creatinine: 67.
Microalbuminuria: negative. Serum cholesterol: 4.0 mmol/l.Case 4 risk assessment
This is a case of high cardiovascular risk due to manifest
coronary artery disease, continued smoking, and elevated
blood pressure. SCORE cannot be assessed as manifest
coronary disease is present. The ESC score is 3.
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70% of GPs wanted to increase hypertension treatment,
with ACE inhibitors being the most common choice (55%),
followed by thiazides (28%). Smoking was identified as a
treatable risk factor by 85% of GPs.
Case 5 facts: male, age 77 years, BP 170/95
Retired, married, physically active man. No family history
of cardiovascular disease. Non-smoker; drinks alcohol
very modestly. Exercises regularly. Healthy diet. No other
diseases. Presently has occasional discomfort in his left
arm; in connection with this, his BP is measured and
found to be high. Exercise stress ECG: normal. Blood
pressure, as measured by a nurse, is 170/95 and 150/85;
at the next visit, his BP is 155/80. BMI: 22 kg/m2. ECG:
normal. Routine tests: NAD. Serum cholesterol: 6.2 mmol/l.
Case 5 risk assessment
This is a case of medium cardiovascular risk with a
medium hypertension levels. SCORE cannot be assessed
in patients of this age. The ESC score is 2.
Case 5 results
58% of GPs wanted to start treatment with the aim of
achieving the target BP (mean 140/86). Of these GPs,
58% selected thiazides as their first choice of treatment;
21% chose ACE inhibitors and 17% beta blockers 17%.
18% of GPs wanted to treat the raised cholesterol levels.
Summary of results Tendency to under-treat was par-
ticularly evident for cases 4 and 5, with just 70 and 58%
of GPs willing to treat these patients, respectively. Con-
versely, the present guidelines give no support for treat-
ment in case no 1 with mild hypertension whereas the
clinicians overwhelmingly chose to treat.
ACE inhibitors and thiazides were the most popular
drug choices, in accordance with guidelines and local
recommendations. For cases 1 and 5 (a young woman
and an old man, respectively), thiazides were the preferred
drugs. For case 2, who had a target organ damage (LVH), a
rather low proportion of GPs (43%) were choosing ACE
inhibitors, which have best evidence for effectiveness for
this condition.
There were a number of suggestions for treating other
risk factors, with concentration on smoking cessation
and non-pharmacological treatment of obesity. In case 3,
a patient with type 2 diabetes, the responses show that
the guidelines concerning treatment of hypertension
when diabetes is present were well understood by GPs.
Discussion
The results of the present study, showed under- as well
as overtreatment in the majority of the presented cases,emphasizing the need for better use of guidelines for the
treatment of hypertension.
Case-based questionnaires aim to illustrate how judg-
ment concerning treatment is made in cases of different
severity. The cases provide a description of a real clinical
challenge in a realistic clinical setting. It is important to
receive a high response rate, and in order to achieve this
the amount of information for the case presentation has
to be reasonable. In this study, the participating GPs
were randomly selected. Together with the high partici-
pation rate, this adds to the credibility of the results.
In addition, the cases were reasonably varied in terms
of overall cardiovascular risk factor burden.
Our study has some limitations. A questionnaire is not
the same as clinical practice, where decisions on treat-
ment take place in concordance with the wishes of the
patient, and in itself, the questionnaire may induce a
more active approach than real life. Also, although
guidelines do exist, there are no correct answers as such
for individual cases. It should also be pointed out that
the responders completed the questionnaires during office
hours with a normal patient load and may thus not have
had adequate time to consider the clinical implications for
each case. This may have caused inconsistencies regarding
the answers.
Perceived lack of time may also show the difficulty of
implementing the SCORE system as a method for use in
clinical practice. It could be used as a guideline, but not
for automatically translating data from population stud-
ies to clinical practice. On the other hand, cases may be
used as an educational method to increase the awareness
of treatment options, as well as a method of priority [7].
Assessment by the ESH and SCORE methods has been
questioned, particularly their failure to indicate the same
CV risk levels [8]. For example, the SCORE system does
not include diabetes as a risk factor. Also, further risk as-
sessment tools tailored to primary care have recently
been proposed [9]. Regarding the generalisability of the
results, the answers came from a particular setting, but
the cases used should be familiar in the Western world.
The results show that correctly assessing risk is difficult,
affecting the consequent choice of treatment.
Finally, our questionnaire has not been validated, which
makes the reproducibility of the responses uncertain. It
would be difficult to find a method of validation since all
information of the patient cannot be provided.
Recently, the awareness-to-adherence model has been
presented [10] in an attempt to explain failures to reach
the blood pressure target. This model could also show
that guidelines are on their own insufficient, and should
be complemented by educational efforts.
Self-report studies have described treatment in clinical
practice [11,12]. However, these studies have been lim-
ited to BP targets and the reasons for not intensifying
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familiarity with research methods, were addressed in a
large survey [13]. Some geographic differences in atti-
tudes concerning age and the cost of medication have
also been reported [14]. When co-morbidity is taken
into consideration, younger physicians are more likely
to follow guidelines [15], a finding we could not con-
firm. This may also be true for non-pharmacological
recommendations [16].
Although frequently commented by our responders,
we have not quantified this particularly.
A case-based method could be of help in the assess-
ment of judgments made by the clinicians. Indeed, this
has been used for other diagnoses [17], but the use of
the method is rare for the treatment of high BP, and thus
we find our study adding to present knowledge.
The difficulty in showing adherence to guidelines due to
different risk levels was described by Milchak et al [18].
Previous studies [19] have also shown limited correlation
between increased number of risk factors and increased
levels of treatment. Another study [20] showed that physi-
cians tend to focus rather on diastolic blood pressure
when choosing treatment, leaving systolic hypertension
less well controlled. Our findings rather contradict this
and thus, our findings confirm that there is much room
for improvement in the assessment of CVD risk. E.g., this
is illustrated in case 5, where the low treatment rate may
be due to reluctance to treat older patients, although this
may be the group which would have the greatest benefit
from treatment [21]. However, when it comes to treatment
of the oldest, a Swedish study showed that lower systolic
blood pressure may be associated with greater mortality in
patients aged 85 or more. [22]
Factors causing reluctance to treat high BP may thus
include hesitance about the guidelines, partly due to doubts
concerning the effectiveness of additive treatment (referred
to by some as “over-treatment”), difficulty in being up-to
date, but also lack of time with patients and GPs concerns
about lack of compliance.
The importance for adequate prevention for patients
at risk is evident. This leads to the objective to increase
adherence to guidelines, to put into practice what is con-
sidered an improved treatment, and in this process the
cases in the questionnaire may be complemented by a
structured study program showing the relative impact of
different risk factors. Then it is of major importance that
the guidelines give similar recommendations for treatment.
Conclusions
The present study confirmed the lack of adherence to
present hypertension guidelines. Indeed, where additional
risk factors are present, the guidelines do not seem to in-
crease the tendency to initiate treatment. It may be easier
to recognise an isolated BP value than to deal with morecomplex patient cases in which different risk factors
should be taken into consideration.
For the future, since hypertension is common in
primary care, we believe research emphasis should be
put on efforts to increase the awareness and thus the
adherence to guidelines in this setting. Computer-based
tools allowing new – medical and educational- data to be
readily available could prove useful for this purpose.
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